Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC lessened its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 51.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 17,676 shares of the company’s stock after selling 18,787 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Caribou Biosciences were worth $101,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its position in Caribou Biosciences by 168.4% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,945 shares of the company’s stock valued at $36,000 after acquiring an additional 2,475 shares during the period. NewEdge Advisors LLC increased its position in Caribou Biosciences by 187.3% in the 1st quarter. NewEdge Advisors LLC now owns 5,100 shares of the company’s stock valued at $27,000 after acquiring an additional 3,325 shares during the period. Penserra Capital Management LLC acquired a new position in Caribou Biosciences in the 1st quarter valued at about $61,000. Tower Research Capital LLC TRC increased its position in Caribou Biosciences by 88.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,871 shares of the company’s stock valued at $29,000 after acquiring an additional 3,218 shares during the period. Finally, Royal Bank of Canada increased its position in Caribou Biosciences by 52.3% in the 2nd quarter. Royal Bank of Canada now owns 8,106 shares of the company’s stock valued at $34,000 after acquiring an additional 2,785 shares during the period. Institutional investors and hedge funds own 77.51% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price objective on Caribou Biosciences from $23.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, March 19th.

Caribou Biosciences Trading Down 3.0 %

Shares of CRBU opened at $4.20 on Monday. Caribou Biosciences, Inc. has a twelve month low of $3.44 and a twelve month high of $8.59. The stock’s 50 day moving average is $6.10 and its two-hundred day moving average is $5.47. The firm has a market capitalization of $379.34 million, a PE ratio of -2.90 and a beta of 2.47.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.17 million. Caribou Biosciences had a negative net margin of 296.05% and a negative return on equity of 31.06%. On average, sell-side analysts predict that Caribou Biosciences, Inc. will post -1.76 EPS for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.